Pacira BioSciences, a pharmaceutical company, completed the acquisition of Flexion Therapeutics, a biopharmaceutical company, for $630m including debt. “This combination with Pacira offers Flexion stakeholders excellent prospects for value creation, particularly as the contingent value rights provide the opportunity to continue to benefit from the ongoing success of Flexion’s products and programs. I’d like to thank all of our employees - past and present - for their extraordinary commitment and superb contributions that have translated into ZILRETTA, a medicine that matters, getting to increasing numbers of patients in need and to a pipeline of potentially transformative medicines,” Michael Clayman, Flexion Co-Founder and CEO.